GSK and Synta announce STA-4783 collaboration

LONDON, UK—GlaxoSmithKline and Synta Pharmaceuticals Corp have reached an agreement for the joint development and commercialization of STA-4783 (elesclomol), a first-in-class, small-molecule oxidative stress inducer that is entering phase III development for the treatment of metastatic melanoma (see page 19). The companies will share responsibility for development of STA-4783 in the United States, and GSK will have exclusive responsibility for development outside the US.